Form DEF 14A Acumen Pharmaceuticals For: 23 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Acumen Pharmaceuticals Inc (ABOS)
Acumen Pharmaceuticals Inc stock price live, this page displays NASDAQ ABOS stock exchange data. View the ABOS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Acumen Pharmaceuticals Inc real time stock price chart below.
What Is the Acumen Pharmaceuticals Inc Stock Price Today?
The Acumen Pharmaceuticals Inc stock price today is 2.670.
What Is the Stock Symbol for Acumen Pharmaceuticals Inc?
The stock symbol for Acumen Pharmaceuticals Inc is "ABOS."
What Stock Exchange Does Acumen Pharmaceuticals Inc Trade On?
Acumen Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Acumen Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Acumen Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABOS quote. (ISIN: US00509G2093)
What Is the Acumen Pharmaceuticals Inc Stock Price Today?
The Acumen Pharmaceuticals Inc stock price today is 2.670.
What Is the Stock Symbol for Acumen Pharmaceuticals Inc?
The stock symbol for Acumen Pharmaceuticals Inc is "ABOS."
What Stock Exchange Does Acumen Pharmaceuticals Inc Trade On?
Acumen Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Acumen Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Acumen Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABOS quote. (ISIN: US00509G2093)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.670
2.880
52 wk Range
0.959
3.600
ABOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.6702.880
52 wk Range
0.9593.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABOS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
7.400
Upside
+177.15%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form S-3 Acumen Pharmaceuticals Inc For: 26 March
- Investing.com
- Form DEF 14A Acumen Pharmaceuticals For: 23 April
- Investing.com
- Form S-3 Acumen Pharmaceuticals Inc For: 26 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Acumen Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Acumen reported $121.3M net loss for 2025, driven by R&D costs for ALTITUDE-AD Phase II Alzheimer's trial; stock fell 3.38% in pre-market.
- Company holds $116.9M in cash reserves after $35.75M private placement, projected to fund operations through early 2027.
- ALTITUDE-AD Phase II trial enrollment completed; topline results for Sabirnetug monoclonal antibody expected late 2026.
- IND filing planned for Enhanced Brain Delivery program by mid-2027; analyst price targets range from $4-$10 per share.
- R&D expenses surged to $104.9M while G&A costs decreased to $18.9M; CEO cited strong institutional confidence in Alzheimer's pipeline.
Last Updated: 2026-03-26, 08:56 a/m
Read Full TranscriptCompare ABOS to Peers and Sector
Metrics to compare | ABOS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABOSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −4.2x | −0.5x | |
PEG Ratio | 0.10 | −0.09 | 0.00 | |
Price/Book | 2.7x | 5.4x | 2.6x | |
Price / LTM Sales | - | 10.1x | 3.2x | |
Upside (Analyst Target) | 184.7% | 177.4% | 45.2% | |
Fair Value Upside | Unlock | 5.8% | 6.4% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.400
(+177.15% Upside)
Earnings
Latest Release
Mar 26, 2026
EPS / Forecast
-0.40 / -0.46
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Acumen Pharmaceuticals (ABOS) Stock Price Today?
The Acumen Pharmaceuticals stock price today is 2.670 USD.
What Stock Exchange Does Acumen Pharmaceuticals Trade On?
Acumen Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Acumen Pharmaceuticals?
The stock symbol for Acumen Pharmaceuticals is "ABOS."
What Is the Acumen Pharmaceuticals Market Cap?
As of today, Acumen Pharmaceuticals market cap is 193.890M USD.
What Is Acumen Pharmaceuticals's Earnings Per Share (TTM)?
The Acumen Pharmaceuticals EPS (TTM) is -2.004.
When Is the Next Acumen Pharmaceuticals Earnings Date?
Acumen Pharmaceuticals will release its next earnings report on May 19, 2026.
From a Technical Analysis Perspective, Is ABOS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Acumen Pharmaceuticals Stock Split?
Acumen Pharmaceuticals has split 0 times.
How Many Employees Does Acumen Pharmaceuticals Have?
Acumen Pharmaceuticals has 61 employees.
What is the current trading status of Acumen Pharmaceuticals (ABOS)?
As of Apr 23, 2026, Acumen Pharmaceuticals (ABOS) is trading at a price of 2.670 USD, with a previous close of 2.810 USD. The stock has fluctuated within a day range of 2.670 USD to 2.880 USD, while its 52-week range spans from 0.959 USD to 3.600 USD.
What Is Acumen Pharmaceuticals (ABOS) Price Target According to Analysts?
The average 12-month price target for Acumen Pharmaceuticals is 7.400 USD, with a high estimate of 10 USD and a low estimate of 4 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +177.15% Upside potential.
What Is the ABOS Premarket Price?
ABOS's last pre-market stock price is 2.780 USD. The pre-market share volume is 139.000, and the stock has decreased by -0.030, or -1.070%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.